Recruiting × Carcinoma, Non-Small-Cell Lung × pembrolizumab × Clear all Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Phase 3 Recruiting
1,210 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
LIMITLESS
Phase 3 Recruiting
30 enrolled
PSI-Immune
Phase 2 Recruiting
880 enrolled
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Phase 1 Recruiting
350 enrolled
DELTA-101
Phase 1 Recruiting
396 enrolled
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2/3 Recruiting
1,260 enrolled
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Phase 3 Recruiting
750 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
INTerpath-009
Phase 3 Recruiting
680 enrolled
INTerpath-002
Phase 3 Recruiting
868 enrolled
TroFuse-007
Phase 3 Recruiting
614 enrolled
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Phase 1 Recruiting
500 enrolled
KANDLELIT-004
Phase 3 Recruiting
600 enrolled
Krascendo 2
Phase 3 Recruiting
600 enrolled
TITER
Phase 1 Recruiting
77 enrolled
KANDLELIT-007
Phase 3 Recruiting
675 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2 Recruiting
252 enrolled
KANDLELIT-013
Phase 3 Recruiting
400 enrolled
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Phase 2 Recruiting
244 enrolled
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Phase 3 Recruiting
400 enrolled
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3 Recruiting
1,410 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
Be6A Lung-02
Phase 3 Recruiting
714 enrolled
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Phase 3 Recruiting
630 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Phase 3 Recruiting
851 enrolled
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Phase 2 Recruiting
318 enrolled
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/2 Recruiting
428 enrolled
RELATIVITY1093
Phase 3 Recruiting
1,000 enrolled
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
880 enrolled
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
340 enrolled
SUNRAY-01
Phase 3 Recruiting
1,264 enrolled
SUNRAY-02
Phase 3 Recruiting
700 enrolled
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
Phase 2 Recruiting
26 enrolled
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 Recruiting
387 enrolled
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Phase 2 Recruiting
105 enrolled
KRAScendo 170
Phase 1/2 Recruiting
320 enrolled
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Phase 2/3 Recruiting
806 enrolled
SYNERGY-101
Phase 1/2 Recruiting
364 enrolled
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
416 enrolled
MK-3475-01A
Phase 1/2 Recruiting
450 enrolled
TROPION-Lung10
Phase 3 Recruiting
675 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Phase 2 Recruiting
28 enrolled
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/2 Recruiting
616 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
ARTEMIDELung04
Phase 3 Recruiting
830 enrolled